Search for dissertations about: "pk pd"
Showing result 1 - 5 of 30 swedish dissertations containing the words pk pd.
-
1. Pharmacometric Models for Antibacterial Agents to Improve Dosing Strategies
Abstract : Antibiotics are among the most commonly prescribed drugs. Although the majority of these drugs were developed several decades ago, optimal dosage (dose, dosing interval and treatment duration) have still not been well defined. READ MORE
-
2. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors : Targeting Different Genotypes and Drug-Resistant Variants
Abstract : Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. READ MORE
-
3. Physiologically Based Pharmacometric Models for Colistin and the Immune Response to Bacterial Infection
Abstract : Antibiotic treatment failure might be due to bacterial resistance or suboptimal exposure at target site and there is a lack of knowledge on the interaction between antimicrobial pharmacodynamics (PD) and the immune response to bacterial infections. Therefore, it is crucial to develop tools to increase the understanding of drug disposition to better evaluate antibiotic candidates in drug development and to elucidate the role of the immune system in bacterial infections. READ MORE
-
4. Safety and Efficacy Modelling in Anti-Diabetic Drug Development
Abstract : A central aim in drug development is to ensure that the new drug is efficacious and safe in the intended patient population. Mathematical models describing the pharmacokinetic-pharmacodynamic (PK-PD) properties of a drug are valuable to increase the knowledge about drug effects and disease and can be used to inform decisions. READ MORE
-
5. Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel
Abstract : Paclitaxel (Taxol®) is now widely used against breast, ovarian and non-small-cell lung cancer. Anticancer agents generally have narrow therapeutic indices, often with myelosuppression (mainly neutropenia) as dose-limiting side effect. READ MORE